These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 23286609)

  • 21. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
    Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
    Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom.
    Bermingham SL; Hughes R; Fenu E; Sawyer LM; Boxall E; T Kennedy P; Dusheiko G; Hill-Cawthorne G; Thomas H
    Value Health; 2015 Sep; 18(6):800-9. PubMed ID: 26409607
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C.
    Grieve R; Roberts J; Wright M; Sweeting M; DeAngelis D; Rosenberg W; Bassendine M; Main J; Thomas H
    Gut; 2006 Sep; 55(9):1332-8. PubMed ID: 15994216
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of groups with poor cost-effectiveness of peginterferon plus ribavirin for naïve hepatitis C patients with a real-world cohort and database.
    Tsai PC; Liu TW; Tsai YS; Ko YM; Chen KY; Lin CC; Huang CI; Liang PC; Lin YH; Hsieh MY; Hou NJ; Huang CF; Yeh ML; Lin ZY; Chen SC; Dai CY; Chuang WL; Huang JF; Yu ML
    Medicine (Baltimore); 2017 Jun; 96(22):e6984. PubMed ID: 28562549
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
    Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
    JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.
    Siebert U; Sroczynski G; Rossol S; Wasem J; Ravens-Sieberer U; Kurth BM; Manns MP; McHutchison JG; Wong JB; ;
    Gut; 2003 Mar; 52(3):425-32. PubMed ID: 12584228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
    Sullivan SD; Jensen DM; Bernstein DE; Hassanein TI; Foster GR; Lee SS; Cheinquer H; Craxi A; Cooksley G; Klaskala W; Pettit K; Patel KK; Green J
    Am J Gastroenterol; 2004 Aug; 99(8):1490-6. PubMed ID: 15307866
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C.
    Younossi ZM; Singer ME; McHutchison JG; Shermock KM
    Hepatology; 1999 Nov; 30(5):1318-24. PubMed ID: 10534357
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non-Cirrhotic Patients: A Societal Perspective.
    Elsisi GH; Aburawash A; Waked E
    Value Health Reg Issues; 2017 Sep; 13():7-15. PubMed ID: 29073993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?
    Marcellusi A; Viti R; Damele F; Cammà C; Taliani G; Mennini FS
    Clin Drug Investig; 2016 Aug; 36(8):661-72. PubMed ID: 27234943
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.
    Najafzadeh M; Andersson K; Shrank WH; Krumme AA; Matlin OS; Brennan T; Avorn J; Choudhry NK
    Ann Intern Med; 2015 Mar; 162(6):407-19. PubMed ID: 25775313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C.
    Sagmeister M; Wong JB; Mullhaupt B; Renner EL
    Eur J Gastroenterol Hepatol; 2001 May; 13(5):483-8. PubMed ID: 11396525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden.
    Sennfält K; Reichard O; Hultkrantz R; Wong JB; Jonsson D
    Scand J Gastroenterol; 2001 Aug; 36(8):870-6. PubMed ID: 11495084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cost-utility analysis of triple therapy with telaprevir in treatment-naïve hepatitis C patients].
    Buti M; Gros B; Oyagüez I; Andrade RJ; Serra MA; Turnes J; Casado MA
    Farm Hosp; 2014 Sep; 38(5):418-29. PubMed ID: 25344136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost effectiveness of combination therapy for hepatitis C: a decision analytic model.
    Stein K; Rosenberg W; Wong J
    Gut; 2002 Feb; 50(2):253-8. PubMed ID: 11788569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.
    Zhang S; Bastian ND; Griffin PM
    BMC Gastroenterol; 2015 Aug; 15():98. PubMed ID: 26239358
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness analysis of simeprevir in combination with peginterferon and ribavirin for treatment-naïve chronic hepatitis C genotype 1 patients in Japan.
    Kuwabara H; Westerhout K; Treur M; Cerri K; Mahlich J; Yatsuhashi H
    J Med Econ; 2015; 18(7):502-11. PubMed ID: 25763827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice.
    Grishchenko M; Grieve RD; Sweeting MJ; De Angelis D; Thomson BJ; Ryder SD; Irving WL;
    Int J Technol Assess Health Care; 2009 Apr; 25(2):171-80. PubMed ID: 19331708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessing the cost-effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia.
    Visconti AJ; Doyle JS; Weir A; Shiell AM; Hellard ME
    J Gastroenterol Hepatol; 2013 Apr; 28(4):707-16. PubMed ID: 23173753
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [New drugs for hepatitis C].
    Färkkilä M
    Duodecim; 2014; 130(18):1813-22. PubMed ID: 25558623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.